Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Albertson Tina M.

(Last) (First) (Middle)


(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
3. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option (right to buy) (1) 08/09/2030 Common Stock 500,000 5.81 D
Option (right to buy) (2) 11/16/2030 Common Stock 400,000 5.96 D
Option (right to buy) (3) 03/15/2032 Common Stock 600,000 5.98 D
Explanation of Responses:
1. 1/4 of the option shares vested on July 1, 2021, with the remaining option shares to vest in equal monthly installments over the following thirty-six months.
2. The option shares vest in equal monthly installments over the forty-eight months following December 1, 2020.
3. 12.5% of the option shares shall vest on August 9, 2022, with the remaining option shares to vest in equal monthly installments over the following forty-two months.
Heather Turner, as Attorney-in-Fact 03/29/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.


       Know all by these presents that the undersigned hereby constitutes and
appoints Heather Turner, Charles Newton and Hector Casab of Lyell Immunopharma,
Inc. and Lauren Creel and Allison Peth of Cooley LLP or any of them signing
singly with full power of substitution, the undersigneds true and lawful
attorney in fact to:
(1)		execute for and on behalf of the undersigned, in the undersigneds capacity
as an officer, director or beneficial owner of more than 10% of a registered
class of securities of Lyell Immunopharma, Inc. (the Company) Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the Exchange Act) and the rules
thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;

(2)	do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to execute such Forms 3, 4 or 5 or Form ID
(including any amendments thereto) and timely file such forms with the United
States Securities and Exchange Commission and any stock exchange or similar
authority; and
(3)	take any other action of any nature whatsoever in connection with the
foregoing which in the opinion of such attorney-in-fact may be of benefit in the
best interest of or legally required by the undersigned, it being understood
that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-facts discretion.
       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary or proper to be done in the exercise of any of the rights
and powers herein granted as fully to all intents and purposes as the
undersigned might or could do if personally present with full power of
substitution or revocation hereby ratifying and confirming all that such
attorney-in-factor such attorney-in-facts substitute or substitutes shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming nor is Lyell Immunopharma, Inc. assuming any of
the undersigneds responsibilities to comply with Section 16 of the Exchange Act.
       This Power of Attorney shall remain in full force and effect until the
earliest to occur of (a) the undersigned is no longer required to file Forms 3,
4 and 5 with respect to the undersigneds holdings of and transactions in
securities issued by the Company, (b) revocation by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact or (c) as to any
attorney-in-fact individually until such attorney-in-fact is no longer employed
by Lyell Immunopharma, Inc. or Cooley LLP.
       IN WITNESS WHEREOF the undersigned has caused this Power of Attorney to
be executed as of this 8th day of March 2022.

						/s/ Tina M. Albertson
						Tina M. Albertson